Study: 'Little incentive’ for drugmakers to complete confirmatory trials for accelerated approvals
Regulatory NewsJeff Craven
Biologics/ biosimilars/ vaccinesClinical TrialsNorth AmericaPharmaceuticalsProduct LifecycleRegulatory Intelligence/PolicyRegulatory NewsJeff CravenBiologics/ biosimilars/ vaccinesClinical TrialsNorth AmericaPharmaceuticalsProduct LifecycleRegulatory Intelligence/Policy